Cover Image
市場調查報告書

生物標記相關合作契約

Global Biomarker Partnering Terms and Agreements 2010-2016: Deal Trends, Players and Financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 229876
出版日期 內容資訊 英文 646 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物標記相關合作契約 Global Biomarker Partnering Terms and Agreements 2010-2016: Deal Trends, Players and Financials
出版日期: 2016年10月05日 內容資訊: 英文 646 Pages
簡介

本報告提供生物醫藥品產業的生物標記的交易結構,實際交易的相關案例研究、調查交易趨勢。並可點閱800份以上的契約書,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 生物標記相關交易趨勢

  • 簡介
  • 過去數年的生物標記合作
  • 大型製藥公司的生物標記交易活動
  • 對生物標記相當消極的大型製藥公司
  • 生物標記合作:不同的交易型態
  • 生物標記合作:不同疾病
  • 生物標記的平均交易條件

第3章 主要的生物標記契約

  • 簡介
  • 金額最高契約
  • 大型製藥公司仲介的主要契約

第4章 大型製藥公司的生物標記契約

  • 簡介
  • 大型製藥公司的生物標記合作契約有效利用法
  • 企業簡介

第5章 生物標記契約名錄

  • 簡介
  • 各開發階段
  • 不同的交易型態
  • 各治療領域

第6章 生物標記契約:各技術類型

第7章 生物標記合作資源中心

  • 線上
  • 活動
  • 參考文獻

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2105

The Global Biomarker Partnering Terms and Agreements 2010-2016: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in biomarker partnering deals
  • Biomarker partnering agreement structure
  • Biomarker partnering contract documents
  • Top biomarker deals by value
  • Most active biomarker dealmakers

The Global Biomarker Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Biomarker agreements announced in the healthcare sectors.

A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.

The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.

The report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the biomarker partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 1,000 online deals records of actual biomarker deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all Biomarker partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual Biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of Biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biomarker dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Biomarker deals since 2010. Deals are listed by headline value, signed by big pharma, most active Biomarker dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biomarker dealmaking with a brief summary followed by a comprehensive listing of Biomarker deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Biomarker partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Biomarker partnering deals signed and announced since Jan 2010. The chapter is organized by specific Biomarker technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Biomarker partnering company A-Z, deal type definitions and Biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Biomarker partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biomarker technologies and products.

Key benefits

Global Biomarker Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of biomarker deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of biomarker agreements with numerous real life case studies
  • Detailed access to actual biomarker contracts enter into by the leading fifty bigpharma companies
  • Access to most active biomarker dealmakers since 2010
  • Insight into the terms included in a biomarker agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Biomarker Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Biomarker Partnering Terms and Agreements includes:

  • Trends in biomarker dealmaking in the biopharma industry since 2010
  • Analysis of biomarker deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life biomarker deals
  • Access to biomarker contract documents
  • The leading biomarker deals by value since 2010
  • Most active biomarker dealmakers since 2010
  • The leading biomarker partnering resources

In Global Biomarker Partnering 2010-2016: Deal trends, players, financials and forecasts, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Biomarker Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,000 biomarker deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise biomarker rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Biomarker Partnering 2010-2015 provides the reader with the following key benefits:

  • In-depth understanding of biomarker deal trends since 2010
  • Analysis of the structure of biomarker agreements with numerous real life case studies
  • Comprehensive access to over 1,000 actual biomarker deals entered into by the world's biopharma companies, together with real world clause examples
  • Access to headline, upfront, milestone and royalty data
  • Full listing of biomarker deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading biomarker deals by value since 2010
  • Identify the most active biomarker dealmakers since 2010
  • Detailed access to actual biomarker deals and contracts enter into by the leading fifty big pharma companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Biomarker dealmaking

  • 2.1. Introduction
  • 2.2. Biomarker partnering over the years
  • 2.3. Most active Biomarker dealmakers
  • 2.4. Biomarker partnering by deal type
  • 2.5. Biomarker partnering by therapy area
  • 2.6. Deal terms for Biomarker partnering
    • 2.6.1 Biomarker partnering headline values
    • 2.6.2 Biomarker deal upfront payments
    • 2.6.3 Biomarker deal milestone payments
    • 2.6.4 Biomarker royalty rates

Chapter 3 - Leading Biomarker deals

  • 3.1. Introduction
  • 3.2. Top Biomarker deals by value

Chapter 4 - Most active Biomarker dealmakers

  • 4.1. Introduction
  • 4.2. Most active Biomarker dealmakers
  • 4.3. Most active Biomarker partnering company profiles

Chapter 5 - Biomarker contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Biomarker contracts dealmaking directory

Chapter 6 - Biomarker dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Biomarker deals by company A-Z

Appendix 2 - Biomarker deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Biomarker deals by deal type

  • Asset purchase
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination

Appendix 4 - Biomarker deals by therapy area

  • Cardiovascular
  • Central Nervous System
  • Dental
  • Dermatology
  • Gastrointestinal
  • Genetic disorders
  • Genitourinary
  • Gynaecology
  • Hematology
  • Hospital care
  • Immunology
  • Infectives
  • Metabolic
  • Musculoskeletal
  • Obstetrics
  • Oncology
  • Ophthalmics
  • Pediatrics
  • Psychiatry
  • Respiratory

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Biomarker partnering since 2010
  • Figure 2: Active Biomarker dealmaking activity- 2010 to 2016
  • Figure 3: Biomarker partnering by deal type since 2010
  • Figure 4: Biomarker partnering by disease type since 2010
  • Figure 5: Biomarker deals with a headline value
  • Figure 6: Biomarker deals with an upfront value
  • Figure 7: Biomarker deals with a milestone value
  • Figure 8: Biomarker deals with a royalty rate value
  • Figure 9: Top Biomarker deals by value since 2010
  • Figure 10: Most active Biomarker dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top